Selective Serotonin Reuptake Inhibitor (SSRI) News and Research

RSS

Selective Serotonin Reuptake Inhibitor (SSRI) is a type of drug that is used to treat depression. SSRIs slow the process by which serotonin (a substance that nerves use to send messages to one another) is reused by nerve cells that make it. This increases the amount of serotonin available for stimulating other nerves. Also called selective serotonin reuptake inhibitor.

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

Several weeks after mild brain ischemia, mice display a depressive-like syndrome characterized by increased anxiety, inactivity and "cheerlessness". These symptoms of depression following a stroke are associated with the delayed loss of nerve cells in the brain's reward regions. This is the major finding of a study published in the current issue of Biological Psychiatry.

16 May 2012

Everett Labs announces availability of Pregnitude for women with fertility problems

A new non-prescription Reproductive Support Dietary Supplement, Pregnitude, which contains myo-inositol (2 g), plus folic acid (200 mcg), is now available for women who are having difficulty conceiving, Everett Laboratories announced today. In clinical studies, Pregnitude has been shown to help support ovulation function and menstrual cycle regularity as well as support the quality of a woman's eggs.

8 May 2012

Autism symptoms treatment using antidepressant SSRIs may not be effective: Review

According to a new review of published and unpublished research, the belief that certain antidepressants can help to treat repetitive behaviors in kids with autism may be based on incomplete information.

24 Apr 2012

PTSD could be genetically predicted

PTSD can occur after any kind of experience that causes trauma, whether that be in war, after a natural disaster or because of child abuse or sexual assault. Symptoms can include flashbacks, feeling emotionally numb or hyper-alert to danger, and avoiding situations that act as reminders of the original trauma. It is estimated that up to 3% of the general population is likely to be affected by PTSD at some point.

5 Apr 2012

Women exposed to SSRIs during pregnancy are less likely to initiate breastfeeding

Researchers at the California Teratogen Information Service (CTIS) Pregnancy Health Information Line, a statewide non-profit organization based at the University of California, San Diego School of Medicine, have found women exposed to certain antidepressants during pregnancy were significantly less likely to breastfeed their babies compared to unexposed women.

9 Mar 2012

Antidepressants in pregnancy: weighing benefits and risks

There has been a debate on the use of antidepressant medication in pregnant women. Depression during pregnancy is, of course, difficult for the woman. In addition, depression that continues in the postpartum period may interfere with caretaking and bonding with the newborn.

5 Mar 2012

SSRI use raises risk of fall among elderly with dementia: Study

A new study reveals that nursing home residents with dementia who use selective serotonin reuptake inhibitors (SSRIs) have an increased risk of having a fall that causes injury compared with those who do not use SSRIs. Additionally those using average doses have 3 times the risk compared with nonusers, the authors, led by Carolyn S. Sterke, from Erasmus University Medical Center, Rotterdam, the Netherlands, report. Authors write, “Even at low doses, SSRIs are associated with increased risk of an injurious fall in nursing home residents with dementia.”

22 Jan 2012

Positive results from Alkermes ALKS 5461 phase 1/2 study on MDD

Alkermes plc today announced positive topline results from a phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

5 Jan 2012

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $0.91 in the second quarter of fiscal 2012. Reported earnings per share in the second quarter of fiscal 2011 were $1.00.

18 Oct 2011

PE, CT appear to reduce PTSD symptoms in patients with recent traumatic event

Prolonged exposure therapy, cognitive therapy, and delayed prolonged exposure therapy, appear to reduce posttraumatic stress disorder symptoms in patients who have experienced a recent traumatic event, according to a report published Online First by Archives of General Psychiatry, one of the JAMA/Archives journals.

4 Oct 2011

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.12 in the fourth quarter of fiscal 2011.

19 Apr 2011

Antidepressants may increase heart attack or stroke risk in men: Study

...

3 Apr 2011

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.11 in the third quarter of fiscal 2011 after taking a charge for a new product licensing fee of $66.1 million or $0.23 per share, net of tax.

18 Jan 2011

Stigma remains over Major Depressive Disorder

Despite there being 39.1 million people suffering from major depressive disorder (MDD) across the seven major markets, only one third of patients will seek help from a physician, finds latest research from independent analyst Datamonitor.

11 Jan 2011

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010

Study: Characteristics of children with OCD could help predict personalized medicine approach

New research from the Bradley Hasbro Children's Research Center may help clinicians better predict how a child with obsessive compulsive disorder (OCD) will respond to some of the most commonly used treatment approaches. The findings, published in the October issue of the Journal of the American Academy of Child and Adolescent Psychiatry, could help guide important clinical decisions about the best intervention for children with this often debilitating anxiety disorder.

15 Oct 2010

Forest Pharmaceuticals to pay $300 million as penalty for criminal actions

The U.S. Food and Drug Administration (FDA), working in close coordination with the U.S. Department of Justice (USDOJ), today announced that Forest Pharmaceuticals, Inc. entered into a plea agreement in which the company accepted responsibility for criminal actions including distribution of an unapproved new drug, distribution of a misbranded drug, and obstruction of an FDA inspection.

16 Sep 2010

Antidepressants cannot be recommended in children with autism: Study

According to a thorough review published by Cochrane Researchers, commonly prescribed antidepressant drugs cannot be recommended for those suffering from autistic spectrum disorders based on current evidence. They say that there may be benefits of antidepressants in adults diagnosed with autism but similar benefits are not seen in children. These children may suffer extremely adverse effects if they consume selective serotonin reuptake inhibitors (SSRIs).

8 Aug 2010

Forest Laboratories reports first-quarter diluted EPS of $0.39

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011. Excluding the charge related to the United States Department of Justice investigations described below, and a charge of $50.0 million, or $0.17 per share net of tax, for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $0.95 per share.

20 Jul 2010

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

AstraZeneca and Targacept, Inc., today announced the enrollment of the first patient in the Phase 3 clinical development program for TC-5214, a nicotinic channel blocker.

23 Jun 2010